EU/3/16/1827: Orphan designation for the treatment of spinocerebellar ataxia
Table of contents
On 12 January 2017, orphan designation (EU/3/16/1827) was granted by the European Commission to Luis Pereira de Almeida, Portugal, for trans-resveratrol for the treatment of spinocerebellar ataxia.
Treatment of spinocerebellar ataxia
|Orphan designation status||
|EU designation number||
|Date of designation||
Luis Pereira de Almeida
CNC- Center for Neuroscience and Cell Biology of Coimbra
Ed. Fac. Medicina
University of Coimbra
Tel. +35 1966337482
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: